CA 125

Референтні значення:

Раковий антиген 125 (СА 125) – єдиний онкомаркер, рекомендований для клінічного використання в діагностиці та лікуванні раку яєчників.

Опорний діапазон СА 125 становить 0-35 одиниць / мл (0-35 кУ / л).

Опорний рівень 35 кУ / л для СА 125 визначали при обстеженні здорових людей. [1] Відсутність міжнародного стандарту для CA 125 перешкоджає порівнянню між лабораторіями, і значення, отримані за допомогою різних методів, не є взаємозамінними.

Значення сироватки СА 125 мають тенденцію до зниження з віком і настанням менопаузи. Рівні також залежать від раси; концентрація у азіатських і африканських жінок в постменопаузі зазвичай нижча.

ДЖЕРЕЛА:

  1. Shih M, Sokoll L, Chan DW. Ovarian cancer. Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, eds. Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, DC: AACC Press; 2002. 239-52.
  2. Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P. Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem. 1998 Jul. 44(7):1417-22. [Medline].
  3. Munkarah A, Chatterjee M, Tainsky MA. Update on ovarian cancer screening. Curr Opin Obstet Gynecol. 2007 Feb. 19(1):22-6. [Medline].
  4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Ovarian Cancer. Version 3.2012 (Accessed September 6, 2012).
  5. Johari-Ahar M, Rashidi MR, Barar J, Aghaie M, Mohammadnejad D, Ramazani A, et al. An ultra-sensitive impedimetric immunosensor for detection of the serum oncomarker CA-125 in ovarian cancer patients. Nanoscale. 2015 Feb 28. 7 (8):3768-79. [Medline].
  6. Memar B, Aledavood A, Shahidsales S, Ahadi M, Farzadnia M, Raziee HR, et al. The Prognostic Role of Tumor Marker CA-125 in B-Cell non-Hodgkin’s Lymphoma. Iran J Cancer Prev. 2015 Jan-Feb. 8 (1):42-6. [Medline].
  7. Macuks R, Baidekalna I, Donina S. Comparison of different ovarian cancer detection algorithms. Eur J Gynaecol Oncol. 2011. 32(4):408-10. [Medline].
  8. CA125 definitions agreed by GCIG. http://www.gcig.igcs.org/CA125/respdef_nov2005.pdf (Accessed September 6, 2012). November 2005.
  9. Fularz M, Adamiak P, Czepczyński R, Jarząbek-Bielecka G, Rewers A, Kędzia W, et al. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level. Nuklearmedizin. 2015 Aug 3. 54 (4):158-62. [Medline].
  10. Rustin G, Van der Burg ME. on behalf of MRC and EORTC Collaborators. A randomized trial in ovarian cancer of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet. 2010 Oct. Vol 376:Issue 9747.1155: 1155-1163.
  11. Jacobs I, Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan. 4(1):1-12. [Medline].
  12. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin. 1999 Sep-Oct. 49(5):297-320. [Medline].
  13. Liu LY. [Relationship between serum CA125 level and second-look findings in ovarian cancers]. Zhonghua Zhong Liu Za Zhi. 1992 Jul. 14(4):287-9. [Medline].
  14. Meyer T, Rustin GJ. Role of tumour markers in monitoring epithelial ovarian cancer. Br J Cancer. 2000 May. 82(9):1535-8. [Medline].
  15. Nasioudis D, Wilson E, Mastroyannis SA, Latif NA. Prognostic significance of elevated pre-treatment serum CA-125 levels in patients with stage I ovarian sex cord-stromal tumors. Eur J Obstet Gynecol Reprod Biol. 2019 Jul. 238:86-9. [Medline].
  16. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Genetic/Familial High Risk Assessment: Breast and Ovarian. Version 1.2012 (Accessed September 6, 2012).
  17. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003 May. 72(5):1117-30. [Medline].
  18. Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001 Mar. 68(3):700-10. [Medline].
  19. NIH consensus conference. Ovarian cancer. Screening, treatment, and follow-up. NIH Consensus Development Panel on Ovarian Cancer. JAMA. 1995 Feb 8. 273(6):491-7. [Medline].
  20. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Colorectal Cancer Screening. Version 2.2012 (Accessed September 6, 2012).
  21. Fleisher M, Dnistrian A, Sturgeon C, Lamerz R,Witliff J. Practice guidelines and recommendations for use of tumor markers in the clinic. Tumor Markers. Physiology, pathobiology, technology and clinical applications. Washington: AACC Press; 2002. 33–63.
  22. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec. 54(12):e11-79. [Medline].
  23. Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. J Biol Chem. 2001 Jul 20. 276(29):27371-5. [Medline].
  24. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998 Oct-Dec. 13(4):179-87. [Medline].
  25. Kenemans P, van Kamp GJ, Oehr P, Verstraeten RA. Heterologous double-determinant immunoradiometric assay CA 125 II: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem. 1993 Dec. 39(12):2509-13. [Medline].
  26. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer. 2005 Sep-Oct. 15(5):679-91. [Medline].
  27. Colombo N, Peiretti M, Parma G, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010 May. 21 Suppl 5:v23-30. [Medline].
  28. Vasey PA, Herrstedt J, Jelic S,. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma. Ann Oncol. 2005. 16 Suppl 1:i13-5. [Medline].
  29. Michalak M, Gąsiorowska E, Markwitz EN. Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics – our experience. Ginekol Pol. 2015 Apr. 86 (4):256-61. [Medline].
  30. Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 8. 305(22):2295-303. [Medline].
  31. Valentin L, Jurkovic D, Van Calster B, et al. Adding a single CA 125 measurement to ultrasound imaging performed by an experienced examiner does not improve preoperative discrimination between benign and malignant adnexal masses. Ultrasound Obstet Gynecol. 2009 Sep. 34(3):345-54. [Medline].
  32. Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Apr. 10(4):327-40. [Medline].
  33. Pal MK, Rashid M, Bisht M. Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis. Biosens Bioelectron. 2015 Nov 15. 73:146-52. [Medline].
  34. Choi HJ, Lee YY, Sohn I, et al. Comparison of CA 125 alone and risk of ovarian malignancy algorithm (ROMA) in patients with adnexal mass: A multicenter study. Curr Probl Cancer. 2019 Nov 1. 100508. [Medline].
  35. Han KH, Park NH, Kim JJ, et al. The power of the Risk of Ovarian Malignancy Algorithm considering menopausal status: a comparison with CA 125 and HE4. J Gynecol Oncol. 2019 Nov. 30 (6):e83. [Medline]. [Full Text].

Залишити коментар

Ваша e-mail адреса не оприлюднюватиметься. Обов’язкові поля позначені *